Adage Capital Partners’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$40.2M Sell
501,866
-1,452,765
-74% -$120M 0.06% 295
2025
Q4
$167M Buy
1,954,631
+595,165
+44% +$48.8M 0.25% 67
2025
Q3
$106M Buy
1,359,466
+485,649
+56% +$37.9M 0.17% 119
2025
Q2
$68.3M Buy
873,817
+420,551
+93% +$31.4M 0.12% 175
2025
Q1
$32.9M Sell
453,266
-770,627
-63% -$55.2M 0.06% 309
2024
Q4
$90.6M Buy
1,223,893
+389,141
+47% +$27.2M 0.16% 120
2024
Q3
$55.1M Buy
834,752
+185,089
+28% +$13.4M 0.1% 216
2024
Q2
$60M Sell
649,663
-644,300
-50% -$57.1M 0.11% 188
2024
Q1
$124M Buy
1,293,963
+834,818
+182% +$70.1M 0.23% 81
2023
Q4
$35M Buy
+459,145
New +$31.9M 0.07% 281
2023
Q3
Sell
-415,805
Closed -$39.2M 893
2023
Q2
$39.2M Sell
415,805
-113,803
-21% -$9.89M 0.09% 242
2023
Q1
$43.8M Buy
529,608
+135,742
+34% +$10.7M 0.1% 244
2022
Q4
$29.4M Sell
393,866
-107,700
-21% -$8.3M 0.07% 322
2022
Q3
$41.4M Sell
501,566
-96,000
-16% -$9.24M 0.1% 214
2022
Q2
$56.8M Sell
597,566
-54,400
-8% -$5.63M 0.13% 165
2022
Q1
$76.7M Sell
651,966
-13,300
-2% -$1.49M 0.15% 147
2021
Q4
$86.2M Sell
665,266
-4,300
-0.6% -$502K 0.16% 144
2021
Q3
$75.8M Sell
669,566
-6,200
-0.9% -$708K 0.15% 144
2021
Q2
$70M Sell
675,766
-20,200
-3% -$1.9M 0.14% 157
2021
Q1
$58.2M Buy
695,966
+4,000
+0.6% +$338K 0.12% 187
2020
Q4
$63.1M Sell
691,966
-4,700
-0.7% -$390K 0.14% 168
2020
Q3
$55.6M Sell
696,666
-18,285
-3% -$1.43M 0.14% 162
2020
Q2
$49.4M Sell
714,951
-267,750
-27% -$19M 0.13% 184
2020
Q1
$61.8M Buy
982,701
+462,378
+89% +$33.3M 0.18% 142
2019
Q4
$40.5M Sell
520,323
-163,200
-24% -$12.7M 0.1% 243
2019
Q3
$50.1M Sell
683,523
-74,307
-10% -$5.22M 0.12% 203
2019
Q2
$46.7M Sell
757,830
-355,320
-32% -$21.5M 0.12% 217
2019
Q1
$71M Buy
1,113,150
+500,646
+82% +$28.6M 0.18% 147
2018
Q4
$31.3M Sell
612,504
-83,076
-12% -$4.2M 0.09% 256
2018
Q3
$40.4M Sell
695,580
-820,500
-54% -$40.1M 0.09% 259
2018
Q2
$73.6M Sell
1,516,080
-689,325
-31% -$32.2M 0.17% 160
2018
Q1
$103M Buy
2,205,405
+562,029
+34% +$24.4M 0.24% 110
2017
Q4
$61.7M Buy
1,643,376
+965,250
+142% +$35.4M 0.14% 186
2017
Q3
$24.7M Sell
678,126
-905,877
-57% -$34.5M 0.06% 366
2017
Q2
$62.4M Buy
1,584,003
+962,310
+155% +$35.1M 0.15% 183
2017
Q1
$19.5M Sell
621,693
-299,595
-33% -$9.38M 0.05% 406
2016
Q4
$28.8M Sell
921,288
-1,577,385
-63% -$51.1M 0.08% 302
2016
Q3
$100M Sell
2,498,673
-683,100
-21% -$25.7M 0.28% 96
2016
Q2
$106M Sell
3,181,773
-187,002
-6% -$6.4M 0.29% 94
2016
Q1
$99.1M Sell
3,368,775
-414,525
-11% -$11.4M 0.27% 107
2015
Q4
$99.6M Buy
3,783,300
+213,300
+6% +$5.54M 0.26% 115
2015
Q3
$84.6M Buy
3,570,000
+1,068,000
+43% +$25.8M 0.23% 121
2015
Q2
$59.4M Buy
2,502,000
+1,200,000
+92% +$27.1M 0.15% 196
2015
Q1
$30.9M Buy
1,302,000
+307,200
+31% +$6.89M 0.08% 324
2014
Q4
$21.1M Buy
994,800
+283,200
+40% +$5.69M 0.05% 395
2014
Q3
$12.1M Buy
+711,600
New +$11.2M 0.03% 503
2013
Q4
Sell
-1,015,200
Closed -$11.8M 696
2013
Q3
$11.8M Buy
1,015,200
+462,000
+84% +$5.4M 0.03% 479
2013
Q2
$6.2M Buy
+553,200
New +$6.55M 0.02% 571

Other funds holding EW

Adage Capital Partners's EW Position: Q1 2026 in Review

Adage Capital Partners reduced its Edwards Lifesciences (EW) stake by 74% in Q1 2026, selling an estimated $120M and leaving 501,866 shares worth $40.2M. The position accounts for 0.06% of the portfolio, ranked #295.

Adage Capital Partners first reported a position in EW in Q2 2013 and has held it in 48 quarters since. The position peaked at $167M in Q4 2025. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Adage Capital Partners held 501,866 shares of Edwards Lifesciences worth $40.2M as of Q1 2026.
  • Adage Capital Partners sold 1,452,765 Edwards Lifesciences shares in Q1 2026, an estimated $120M.
  • Edwards Lifesciences made up 0.06% of Adage Capital Partners's portfolio in Q1 2026, its #295 holding.
  • Adage Capital Partners first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 48 quarters since.
  • Adage Capital Partners's Edwards Lifesciences position peaked at $167M in Q4 2025.
  • 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.